$SBEV

SPLASH BEVERAGE GROUP, INC. (SBEV): Entry into a Material Definitive Agreement

SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001553788 0001553788 2026-07-10 2026-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor

Original reporting
Published Jul 13, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$SBEV
Bullish
medium confidence
Mentioned
$SBEV
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SBEVBullishMed
01

Why it matters

If the payment is made by Aug. 31, 2026, the lender will release and discharge the company from obligations under the loan agreement, potentially improving balance-sheet risk and future interest/fees exposure.

02

Market read

A specific debt settlement with defined payment amount and discharge terms is disclosed via an 8-K, providing a concrete catalyst for credit/liquidity sentiment.

03

What to watch

Traders may want to check whether the loan agreement had covenants or collateral terms that could affect operations even after the settlement letter, and whether any other obligations remain outstanding.

Relevance 6/10Novelty 7/10Timing: after-hours following the July 13, 2026 8-K filing; settlement deadline is Aug. 31, 2026

Background

The company previously disclosed the underlying Revenue Loan and Security Agreement in a Dec. 31, 2020 8-K; this filing adds a new settlement mechanism.

Company-level read

Ticker impact

$SBEVBullishMedium confidence
Context

Splash Beverage Group entered a letter agreement to settle its $2.83M revenue loan by paying $301,800.55 by Aug. 31, 2026.

Expected impact

Near-term sentiment could be mildly positive, but magnitude depends on how material the loan was to liquidity and any remaining covenants.

Evidence & confidence

This is a primary-source 8-K contract disclosure with specific settlement economics and a clear release condition tied to payment timing.

Market effects

Limited direct read-across; it is company-specific debt restructuring/settlement rather than a sector-wide credit event.

No clear regional spillover indicated by the filing.

No global macro or cross-border implications stated.

Counterpoint

The settlement still requires a large payment by Aug. 31, 2026, so liquidity risk remains if cash generation is weak.

Key entities

  • Splash Beverage Group, Inc.

    Company entering the settlement letter agreement to discharge its revenue loan obligations.

  • Decathlon Alpha IV, L.P.

    Lender under the revenue loan agreement that will release the company upon timely payment.

Related articles

$SBEVMed

Splash Beverage Group (SBEV) Stock Is Trending Overnight— Here's Why It Jumped 64% After Hours Splash Bev

Splash Beverage Group Inc. (NYSE:SBEV) shares are trending on Friday. Shares of the Florida-based company climbed 64.10% to $0.57 after the bell on Thursday. The surge in the late trading session follows an intraday gain of 7.07% which closed the SBEV at $0.35, according to Benzinga Pro data. Splash Beverage Group, which engages in the manufacturing, distribution, marketing, and sale of various beverages, experienced an exceptionally elevated trading session on Thursday.

$SBEVMed

Splash Beverage Group Expands CannEpil Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Splash Beverage Group (NYSE American: SBEV) said it expanded its exclusive global CannEpil license to cover veterinary therapeutics. The company plans initial evaluation for companion-animal oncology and chronic pain, pursuing FDA Center for Veterinary Medicine INAD and Conditional Approval pathways. Splash will pay Argent BioPharma a 10% royalty on veterinary net revenues.

$SBEVMedAI 8/10

Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said it settled legacy creditor claims totaling about $3.3 million for about $550,000 cash, expecting an approximate $2.75 million gain from debt extinguishment, subject to final accounting. Its board approved a 1-for-4 reverse stock split to support NYSE American minimum price compliance, reducing shares from ~25.2M to ~6.3M, effective July 27, 2026.

$SBEVMed

Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said NYSE American accepted its plan to regain continued listing compliance and granted a compliance period through Jan. 29, 2027, after the company submitted the plan on May 29, 2026. The company said it will execute strategic initiatives while maintaining its listing.

$SBEVMedAI 8/10

SPLASH BEVERAGE GROUP ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO CANNEPIL®, AN EPILEPSY THERAPY WITH ESTABLISHED EUROPEAN PATIENT ACCESS, FDA ENGAGEMENT AND U.S. DEVELOPMENT POTENTIAL

Splash Beverage Group (NYSE American: SBEV) said it signed an exclusive global licensing deal with Argent BioPharma (ASX/LSE: RGT) for CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy. CannEpil is approved for distribution in multiple countries and has initiated U.S. pre-IND/IND steps. Splash received a $1M investment commitment and will issue $5.5M preferred equity; Argent debt (~$5M) is forgiven. Argent earns a 15% net-revenue royalty.

$SBEVMed

Splash Beverage Group Secures Exclusive Global Rights To CannEpil For Drug- Resistant Epilepsy

Splash Beverage Group (SBEV) said it secured exclusive global licensing rights to CannEpil, a pharmaceutical-grade cannabinoid therapy for drug-resistant epilepsy, from Argent BioPharma (RGT.AX). CannEpil has patient access in Ireland, UK, Germany and Australia under EU-GMP, with Ireland MCAP reimbursement support and UK Named Patient Request import/prescription. SBEV cited pre-IND/IND progress for U.S. development.